190 related articles for article (PubMed ID: 30964112)
1. Evaluation of efficacy and safety of apatinib treatment in advanced gastric cancer.
Yang Y; Wu X; Li F; Wang N; Zhang M; Sun T; Chen Z
J Cancer Res Ther; 2019; 15(2):365-369. PubMed ID: 30964112
[TBL] [Abstract][Full Text] [Related]
2. Apatinib for advanced nonsmall-cell lung cancer: A retrospective case series analysis.
Yang C; Feng W; Wu D
J Cancer Res Ther; 2018 Jan; 14(1):159-162. PubMed ID: 29516980
[TBL] [Abstract][Full Text] [Related]
3. The safety of apatinib for the treatment of gastric cancer.
Geng R; Song L; Li J; Zhao L
Expert Opin Drug Saf; 2018 Nov; 17(11):1145-1150. PubMed ID: 30324820
[TBL] [Abstract][Full Text] [Related]
4. Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study.
Zhang D; Zhang C; Huang J; Guan Y; Guo Q
Thorac Cancer; 2018 Dec; 9(12):1754-1762. PubMed ID: 30338916
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: A prospective clinical study.
Guo Y; Tang J; Huang XE; Cao J
Medicine (Baltimore); 2019 Feb; 98(6):e13908. PubMed ID: 30732125
[TBL] [Abstract][Full Text] [Related]
6. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Li J; Qin S; Xu J; Xiong J; Wu C; Bai Y; Liu W; Tong J; Liu Y; Xu R; Wang Z; Wang Q; Ouyang X; Yang Y; Ba Y; Liang J; Lin X; Luo D; Zheng R; Wang X; Sun G; Wang L; Zheng L; Guo H; Wu J; Xu N; Yang J; Zhang H; Cheng Y; Wang N; Chen L; Fan Z; Sun P; Yu H
J Clin Oncol; 2016 May; 34(13):1448-54. PubMed ID: 26884585
[TBL] [Abstract][Full Text] [Related]
7. Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study.
Ma X; Li L; Zhang L; Fu X; Li X; Wang X; Wu J; Sun Z; Zhang X; Feng X; Chang Y; Zhou Z; Nan F; Zhang J; Li Z; Zhang M
Drug Des Devel Ther; 2020; 14():275-284. PubMed ID: 32158186
[TBL] [Abstract][Full Text] [Related]
8. Clinical Efficacy and Safety of Apatinib for the Treatment of Patients with Metastatic, Recurrent Cervical Cancer after Failure of Radiotherapy and First-Line Chemotherapy: A Prospective Study.
Xia X; Jiang W; Qi W; Hong B; Zhao W
Oncol Res Treat; 2020; 43(12):649-655. PubMed ID: 33045704
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of apatinib combined with tegafur gimeracil and oteracil potassium in the second-line treatment of advanced gastric cancer.
Chen H; Xue L; Liu L; Li P
J BUON; 2021; 26(3):917-923. PubMed ID: 34268954
[TBL] [Abstract][Full Text] [Related]
10. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.
Li J; Qin S; Xu J; Guo W; Xiong J; Bai Y; Sun G; Yang Y; Wang L; Xu N; Cheng Y; Wang Z; Zheng L; Tao M; Zhu X; Ji D; Liu X; Yu H
J Clin Oncol; 2013 Sep; 31(26):3219-25. PubMed ID: 23918952
[TBL] [Abstract][Full Text] [Related]
11. Apatinib in gastric carcinoma: A case report of partial response for first-line treatment in advanced disease.
Wang Y; Bi M; Zhang H; Gao Z; Zhou H; Chang S
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e528-e530. PubMed ID: 28028915
[TBL] [Abstract][Full Text] [Related]
12. Apatinib for the treatment of gastric cancer.
Roviello G; Ravelli A; Fiaschi AI; Cappelletti MR; Gobbi A; Senti C; Zanotti L; Polom K; Reynolds AR; Fox SB; Generali D
Expert Rev Gastroenterol Hepatol; 2016 Aug; 10(8):887-92. PubMed ID: 27376400
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
Zhao J; Lei J; Yu J; Zhang C; Song X; Zhang N; Wang Y; Zhang S
Invest New Drugs; 2020 Apr; 38(2):500-506. PubMed ID: 31650447
[TBL] [Abstract][Full Text] [Related]
14. Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study.
Li L; Kong F; Zhang L; Li X; Fu X; Wang X; Wu J; Zhang F; Ren L; Zhang M
Invest New Drugs; 2020 Dec; 38(6):1847-1853. PubMed ID: 32363427
[TBL] [Abstract][Full Text] [Related]
15. The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study.
Yu J; Xu Z; Li A; Zhang J; Wang Y; Zhao H; Zhu H
Drug Des Devel Ther; 2019; 13():3419-3424. PubMed ID: 31576114
[TBL] [Abstract][Full Text] [Related]
16. Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial.
Zhou JG; Zhou NJ; Zhang Q; Feng YY; Zhou H
Trials; 2018 Sep; 19(1):500. PubMed ID: 30223869
[TBL] [Abstract][Full Text] [Related]
17. A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer.
Liang L; Wang L; Zhu P; Xia Y; Qiao Y; Wu J; Zhuang W; Fei J; Wen Y; Jiang X
Clin Colorectal Cancer; 2018 Sep; 17(3):e443-e449. PubMed ID: 29576426
[TBL] [Abstract][Full Text] [Related]
18. Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers.
Scott LJ
Drugs; 2018 May; 78(7):747-758. PubMed ID: 29663291
[TBL] [Abstract][Full Text] [Related]
19. Low dosage of apatinib monotherapy as rescue treatment in advanced lung squamous cell carcinoma.
Zeng DX; Lei W; Wang CG; Huang JA; Jiang JH
Cancer Chemother Pharmacol; 2019 Mar; 83(3):439-442. PubMed ID: 30547193
[TBL] [Abstract][Full Text] [Related]
20. Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China.
Xie L; Guo W; Wang Y; Yan T; Ji T; Xu J
BMC Cancer; 2018 Apr; 18(1):396. PubMed ID: 29625604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
